Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
Liposomes protect loaded drug molecules from external degradation, and their similarity to biological membranes provides unique opportunities to deliver drug molecules into cells or subcellular compartments ... In addition, various physicochemical properties of liposomes—including their size, charge, and surface functional ligands—can be altered, resulting in functionalities favoring specific drug delivery tasks. These advantages have made liposomes a leading drug delivery platform with a wide range of uses in the clinic.
Lipid Nanoparticle Drugs are liposome-like structures especially geared towards encapsulating a broad variety of nucleic acids (RNA and DNA); and as such, they are the most popular non-viral gene delivery system. Exelead develops and manufactures LNPs to encapsulate different types of genetic payloads including siRNA, mRNA and saRNA.
LNPs are composed primarily of cationic lipids along with other lipid ingredients. These typically include neutral phospholipid molecules belonging to the phosphatidylcholine (PC) class and sterols, such as cholesterol. Another common lipid ingredient is what is known as a PEGylated phospholipid—a polyethylene glycol (PEG) polymer covalently attached to the head-group of a phospholipid.
Solid lipid nanoparticles (SLNs, sLNPs), or lipid nanoparticles (LNPs), are nanoparticles composed of lipids. They are a novel pharmaceutical drug delivery system (and part of nanoparticle drug delivery), and a novel pharmaceutical formulation. LNPs as a drug delivery vehicle were first approved in 2018 for the siRNA drug, Onpattro. LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market- Key Players
Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, Leadiant Biosciences, Ipsen, Sayre Therapeutics, Jazz, Alnylam, Bausch Health, Acrotech Biopharma, Takeda, Chiesi Farmaceutici, Gilead Sciences, are some of the key players, functioning in the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market. Among those manufacturers, CSPC keeps fastest growth. In 2020, CSPC owned 8.97% revenue share while the market is estimated to be 10.15% in 2021. Gilead Sciences is the largest manufacturers and owns more than 10.5% revenue share globally.
Read More Information: https://www.qyresearch.com/index/detail/3160550/global-liposomal-and-lipid-nanoparticle-drug-delivery-systems-market
QYResearch provides Market Research Reports for clients all over the world. As of now, QYResearch data as following:
62000 + Clients(cover 100% the world strong 500 companies and most industries’ leading players such as TOP5 players)
7800 + Experts(most of them with more than 15 years’ experience in their industry and professional knowledge both in market and technology)
300 + Data Base(40% government related data base, 30% third part data base, 10% international agencies data base, 30% technology and market data base)
2 Million + Reports(cover almost all industries and most detailed products such as product model level research reports, where you can find all what you need in one shop)
1000 + Custom Research Projects(most clients need custom research service and QYResearch keeps offering good and depth service for them)
30 + Roles Data Interview Checking System(only QYResearch uses such interview system with more than 30 roles in order to confirm the data reliability)
13 + Years focus market research and continues to support the client success.
Rahul Singh - Digital Marketing Director
Contact: +91 7028 920 828 +81-903-800-9273 +86-108-294-5717
Sales Contact US:
USA Registered Office: QY Research, INC.
17890 Castleton, Suite 369,
City of industry, CA - 91748
Emails – firstname.lastname@example.org
Web – www.qyresearch.com